SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?


To: Jibacoa who wrote (1168)9/12/2005 2:19:16 PM
From: Jibacoa  Respond to of 3722
 
VICL announced today that it plans to develop electroporation-enhanced delivery of its DNA vaccines against HIV under an agreement with the VRC,NIAID and NIH.

The electroporation technology is licensed from INO, which is down some today.<g>

VICL also announced that it agreed to grant MRK renewable options for rights to use its non-viral gene delivery technology for additional cancer targets.

VICL will have sublicenseable rights to use the technology for vaccines against HIV.

The stock was up 18.48% this morning when it traded at the $5 level at 9.35AM & 11.35AM It started with an upgap which hasn't been closed as the stock is finding support at the 4.74 level in spite of some recent downticks <g>

bigcharts.marketwatch.com

Bernard